MGX (24) ALGS (22) ESLA (39) EVAX (48) ⌘ Pro Terminal →

Genenta Science S.p.A. (GNTA) — RQD Stock Rating Cockpit

$0.62 -0.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.62

Genenta Science S.p.A. (GNTA) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $29.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GNTA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GNTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Genenta Science S.p.A. (NASDAQ: GNTA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.62 (-0.27% 1D, market cap $29.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GNTA ranks #302 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GNTA compare to MGX and ALGS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GNTA carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MGX (Metagenomi Therapeutics Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and ALGS (Aligos Therapeutics Inc.) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M). Among the 5-stock peer group, GNTA leads on earnings multiple (N/A) while MGX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GNTA?

▼

For Genenta Science S.p.A. (GNTA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #302 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.62 (-0.24%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GNTA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY GNTA SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($837.0K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$0.76-13.2% Next Q

Q2 (-2Q)

Grade C$0.66-6.1% Next Q

Q3 (-1Q)

Grade C-$0.62+0% Next Q

Current

Grade D$0.62-1.4% Hist 90D α

Trajectory: C (58) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GNTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GNTA currently carries a cautious 50/100 (D) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.78) and Max Pain ($0.65) forces dealer call-delta covering toward $3.08.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GNTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GNTA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

36.630 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE3% OF RANGE

L: $1$0.62H: $3

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on GNTA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (42)

16/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like GNTA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GNTA)

✓Walkthrough of GNTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GNTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.14%▲ RESISTANCE BREAKOUT

2026-11-02O $0.60H $0.62L $0.60C $0.62VOL 153.2K

RES: $0.48SUP: $0.30SMA50: $0.78SMA200: $1.03

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GNTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GNTA Butterfly Map → + Track GNTA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GNTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GNTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GNTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GNTA)

Health Care Rank #302 of 1016 ⚔️ MGX vs GNTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GNTA vs. MGX, ALGS, ESLA, EVAX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Genenta Science S.p.A. (GNTA) ranks #302 by composite RQD confidence (50/100, grade D) and #804 by equity capitalization ($29.9M). Within this direct 5-issuer industry benchmark cohort, GNTA leads on earnings valuation at N/A trailing P/E, while MGX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GNTA ACTIVE Genenta Science S.p.A.	D	50/100	—	—	—	-0.27%	$29.9M	Benchmark Subject
MGX Metagenomi Therapeutics Inc.	E	24/100	—	—	-35.0%	-6.01%	$31.4M	/mgx-vs-gnta →
ALGS Aligos Therapeutics Inc.	E	22/100	—	—	-35.0%	-4.57%	$31.4M	/algs-vs-gnta →
ESLA Estrella Immunopharma Inc.	D-	39/100	—	—	-35.0%	-12.27%	$31.7M	/esla-vs-gnta →
EVAX Evaxion A/S	D	48/100	—	—	—	-4.87%	$27.8M	/evax-vs-gnta →

2. GNTA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Genenta Science S.p.A. (GNTA) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $29.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. GNTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GNTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GNTA compare to MGX and ALGS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for GNTA?

Where is GNTA trading relative to its 50-day, 200-day, and 52-week technical levels?

GNTA last traded at $0.62 (-0.27% on volume of 67,198 shares), positioning the stock -20.51% below its 50-day simple moving average ($0.78) and -39.81% below its 200-day simple moving average ($1.03). Across its 52-week range of $0.55 to $2.93, GNTA sits at the 2.9% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.70).

GNTA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell GNTA stock right now?

Genenta Science S.p.A. (GNTA) currently earns a Roarable Rating of D (Sell — SELL) with 50/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is GNTA's 12-month price target and RQD AI Jury consensus?

GNTA's 12-month base price target is $0.6 (range $0.47 to $3.08), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: GNTA RQD Cockpit GNTA 12M Forecast GNTA Earnings & Move GNTA Dividends & DRIP GNTA Insiders & 13F GNTA Whale Options GNTA Profit Sankey GNTA News & Why

ROARABLE RATING BRIEF • RQD 50/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GNTA — Genenta Science S.p.A.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:19:36Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, GNTA carries an RQD Score of 50 out of 100, a letter grade of D, and the verdict label "Roarable Sell — Underperform / Distribution Warning." Across the five pillars, the Fundamental Cash Engine scores 12 out of 20, reflecting an ROIC of 0% and an FCF yield of 0%. The Whale 13F Flow pillar scores 7 out of 20 on institutional accumulation and options positioning. The Insider Conviction pillar scores 9 out of 20 on SEC Form 4 and Congressional PTR cluster flow. The Macro Regime Fit pillar scores 9 out of 20, with a Beta of 1.0 and a sector-sensitivity read. The Forensic Balance Sheet pillar scores 13 out of 20, citing an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the upside drivers are limited in the source data: the forensic balance-sheet pillar is the strongest component, while the zero-percent ROIC and FCF yield leave little cash-generation support for the valuation. Valuation tradeoffs cannot be assessed on earnings multiples because P/E and EV/EBITDA are not available in source data. The weakest pillars (institutional flow and insider conviction) indicate that the source data does not show strong accumulation signals. This brief is analytical and educational, not personalized financial advice.

Business

Genenta Science S.p.A. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, it is classified within this industry with a market capitalization of $0.0B. Not available in source data: product lines, customer base, and revenue model.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the most prominent items concern a Nasdaq minimum bid price deficiency notice, reported on two separate occasions. Per the news feed, the company has also adopted the Saentra Forge business name, with one headline noting that shareholders need take no action. The feed further includes a stock price prediction article. All items are tagged as YELLOW with a MARKET WIRE impact label.

Risk watch items: the Nasdaq minimum bid price deficiency notices are the most direct listing-compliance catalysts in the source data. The stock's trading price of 0.62 and 52-week range of $0.55 - $2.93 sit near the low end of that range. Per the Butterfly Supply-Chain Graph, there are no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies are therefore not available in source data. Sector correlations beyond the Health Care sector classification are not available in source data. Second-order bottlenecks are not available in source data.

Open Questions

What revenue, operating income, and cash flow have been reported in recent periods, given that margins and FCF yield are shown as 0%?
What is the current status and timeline for resolving the Nasdaq minimum bid price deficiency, and what remediation options are disclosed?
What is the underlying business and product pipeline behind the Saentra Forge name change?
What is the composition of institutional (13F) and insider (Form 4) ownership, given that holder data is not available?
What analyst coverage and price targets exist for the stock, given that analyst data is not available?

GNTA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Genenta Science S.p.A. (GNTA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GNTA Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 9h ago

Genenta Science S.p.A. Estimates – NASDAQ:GNTA

TradingView report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 12h ago

Shareholders need no action as Genenta adopts the Saentra Forge name

Stock Titan report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 15h ago

Genenta Science receives Nasdaq minimum bid price deficiency notice

TradingView report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 18h ago

A new business name, not a legal-name change: Genenta Science (Nasdaq: GNTA) will use Saentra Forge.

Stock Titan report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Manila Times • 21h ago

Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification

The Manila Times report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Genenta Science S.p.A. ADR (GNTA) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Genenta Science S.p.A. ADR Stock Price Today | GNTA Live Chart & News

Traders Union report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TipRanks • 1d ago

Genenta Science Faces Nasdaq Minimum Bid Price Deficiency, Explores Options to Preserve Listing

TipRanks report covering Genenta Science S.p.A. (GNTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GNTA Bull vs. Bear Conversation Board — What's Your Call at $0.62?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GNTA 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $0.67 (+8.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GNTA (D • RQD 50/100) a Buy at $0.62?

Welcome to the GNTA (Genenta Science S.p.A.) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.47 (-24.2%)

Spot @ $0.62

Pump the brakes on GNTA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GNTA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Genenta Science S.p.A. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.79 (+27.4%)

Spot @ $0.62

GNTA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GNTA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.62 (52-wk range $0.55 - $2.93), any beat on forward guidance forces shorts and underweight funds to chase.